In this multi-institutional study of 77 patients with CHL-RT (27 type 1 and 50 type 2), we characterized immune evasion markers, <i>PD-L1</i> / <i>PD-L2</i> copy number alterations, tumor microenvironment, and performed targeted next-generation sequencing on 37 CLL/SLL samples. This evidence concerns the gene PDCD1LG2 and neoplasm.